
    
      Study design: Prospective multi-center non-interventional cohort study Data Source(s):
      Medical records of patients who are treated with durvalumab following chemoradiation therapy
      Study Population: Patients prescribed and treated with durvalumab for unresectable stage III
      non-small cell lung cancer (NSCLC) at first time following chemoradiation therapy and who
      provide written informed consent.

      Exposure(s): durvalumab Outcome(s): Summary of pneumonitis and adverse event special interest
      (AESI), progression free survaival (PFS), overall survaival (OS), Reasons of discontinuation
      of durvalumab treatment, Details of subsequent treatments after durvalumab Sample Size
      Estimations: 500 patients Statistical Analysis: Only descriptive analysis and no formal test
    
  